Therapeutic advances in relapsed or refractory multiple myeloma

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 11, Issue 5 SUPPL., 2013, Pages 676-679

  Anderson, Kenneth C ^a,b,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b LeBow Institute for Myeloma Therapeutics   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC ALKALOID; BENDAMUSTINE; BHQ 880; BORTEZOMIB; CARFILZOMIB; CYCLOPHOSPHAMIDE; DACETUZUMAB; DARATUMUMAB; DEXAMETHASONE; ELOTUZUMAB; INTERLEUKIN 6 ANTIBODY; IXAZOMIB CITRATE; LENALIDOMIDE; LUCATUMUMAB; MONOCLONAL ANTIBODY; NBT 026; NBT 062; POMALIDOMIDE; RAP 011; RICOLINOSTAT; THALIDOMIDE; UNCLASSIFIED DRUG; VORINOSTAT; XMAB 5592;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; APOPTOSIS; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CELL CYCLE ARREST; CLINICAL TRIAL (TOPIC); COMORBIDITY; COMPLEMENT DEPENDENT CYTOTOXICITY; CONFERENCE PAPER; CONSOLIDATION CHEMOTHERAPY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG POTENCY; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG WITHDRAWAL; HUMAN; LOW DRUG DOSE; MAINTENANCE CHEMOTHERAPY; MOLECULARLY TARGETED THERAPY; MULTIPLE MYELOMA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; PROGRESSION FREE SURVIVAL; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 84887476028     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2013.0199     Document Type: Conference Paper

References (16)

1. Terragna C, Zamagni E, Petrucci MT=, et al. Molecular remission after bortezomib-thalidomide-dexamethasone compared with thalidomide-dexamethasone as consolidation therapy following double autologous transplantation for multiple myeloma: results of a qualitative and quantitative analysis. Haematologica 2011;96(s1):S96. Abstract P224.
2. McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012;366:1770-1781.
3. Jagannath S, Hofmeister CC, Siegel DS, et al. Pomalidomide with low-dose dexamethasone in patients with relapsed and refractory multiple myeloma who have received prior therapy with lenalidomide and bortezomib: updated phase 2 results and age subgroup analysis [abstract]. Blood 2012;120: Abstract 450.
4. Lacy MQ, Kumar S, LaPlant B, et al. Pomalidomide plus low-dose dexamethasone in relapsed myeloma: long term follow-up and factors predicting outcome in 345 patients [abstract]. Blood 2012;120: Abstract 201.
5. Dimopoulos MA, Lacy MQ, Moreau P, et al. Pomalidomide in combination with low-dose dexamethasone demonstrates a significant progression-free survival and overall survival advantage in relapsed/refractory multiple myeloma: a phase 3, multicenter, randomized, open-label study [abstract]. Blood 2012;120: Abstract 6.
6. Richardson PG, Hofmeister CC, Siegel D, et al. MM-005: A phase 1, multicenter, open-label, dose-escalation study to determine the maximum tolerated dose for the combination of pomalidomide, bortezomib, and low-dose dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma [abstract]. Blood 2012;120: Abstract 727.
7. Siegel DS, Martin T, Wang M, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 2012;120:2817-2825.
8. Wang W, Bensinger W, Martin T, et al. Interim results from PX-171-006, a phase II multicenter dose-expansion study of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed and/or refractory multiple myeloma [abstract]. J Clin Oncol 2011;29(Suppl 15): Abstract 8025.
9. Papadopoulos KP, Lee P, Singhal S, et al. A phase 1b/2 study of prolonged infusion carfilzomib in patients with relapsed and/or refractory multiple myeloma: updated efficacy and tolerability from the completed 20/56 mg/m2 expansion cohort of PX-171-007 [abstract]. Blood 2011;118: Abstract 2930.
10. Richardson PG, Jagannath S, Moreau P, et al. A phase 2 study of elotuzumab in combination with lenalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma: updated rresults [abstract]. Blood 2012;120: Abstract 202.
11. Plesner T, Lokhorst H, Gimsing P, et al. Daratumumab, a CD38 monoclonal antibody in patients with multiple myeloma: data from a dose-escalation phase I/II study [abstract]. Blood 2012;120: Abstract 73.
12. Chauhan D, Tian Z, Nicholson B, et al. A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell 2012;22:345-358.
13. Richardson PG, Baz R, Wang L, et al. Investigational agent MLN9708, an oral proteasome inhibitor, in patients with relapsed and/or refractory multiple myeloma: results from the expansion cohorts of phase 1 dose-escalation study [abstract]. Blood 2011;118: Abstract 301.
14. Delmore JE, Issa GC, Lemieux ME, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011;146:904-917.
15. Dimopoulos ME, Jagannath S, Yoon S-S, et al. Vantage 088: vorinostat in combination with bortezomib in patients with relapsed/refractory multiple myeloma: results of a global, randomized phase 3 trial. Presented at the 2011 American Society of Hematology Annual Meeting. Abstract 811.
16. Santo L, Hideshima T, Kung AL, et al. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood 2012;119:2579-2589.